[1]
Gajdusek DC. Slow-virus infections of the nervous system. The New England journal of medicine. 1967 Feb 16:276(7):392-400
[PubMed PMID: 6066787]
[2]
Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science (New York, N.Y.). 1977 Sep 2:197(4307):943-60
[PubMed PMID: 142303]
[3]
Asher DM, Gregori L. Human transmissible spongiform encephalopathies: historic view. Handbook of clinical neurology. 2018:153():1-17. doi: 10.1016/B978-0-444-63945-5.00001-5. Epub
[PubMed PMID: 29887130]
[4]
GAJDUSEK DC,ZIGAS V, Degenerative disease of the central nervous system in New Guinea; the endemic occurrence of kuru in the native population. The New England journal of medicine. 1957 Nov 14;
[PubMed PMID: 13483871]
[5]
Prusiner SB, Gajdusek C, Alpers MP. Kuru with incubation periods exceeding two decades. Annals of neurology. 1982 Jul:12(1):1-9
[PubMed PMID: 7114816]
[6]
Haywood AM. Transmissible spongiform encephalopathies. The New England journal of medicine. 1997 Dec 18:337(25):1821-8
[PubMed PMID: 9400041]
[7]
Prusiner SB. Shattuck lecture--neurodegenerative diseases and prions. The New England journal of medicine. 2001 May 17:344(20):1516-26
[PubMed PMID: 11357156]
[8]
Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas DJ, Alpers MP. Kuru in the 21st century--an acquired human prion disease with very long incubation periods. Lancet (London, England). 2006 Jun 24:367(9528):2068-74
[PubMed PMID: 16798390]
[9]
Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science (New York, N.Y.). 1982 Apr 9:216(4542):136-44
[PubMed PMID: 6801762]
[10]
Liberski PP, Gajos A, Sikorska B, Lindenbaum S. Kuru, the First Human Prion Disease. Viruses. 2019 Mar 7:11(3):. doi: 10.3390/v11030232. Epub 2019 Mar 7
[PubMed PMID: 30866511]
[11]
GAJDUSEK DC, ZIGAS V. Kuru; clinical, pathological and epidemiological study of an acute progressive degenerative disease of the central nervous system among natives of the Eastern Highlands of New Guinea. The American journal of medicine. 1959 Mar:26(3):442-69
[PubMed PMID: 13626997]
Level 2 (mid-level) evidence
[12]
Alpers MP. Review. The epidemiology of kuru: monitoring the epidemic from its peak to its end. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 2008 Nov 27:363(1510):3707-13. doi: 10.1098/rstb.2008.0071. Epub
[PubMed PMID: 18849286]
[13]
Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR. Physiology of the prion protein. Physiological reviews. 2008 Apr:88(2):673-728. doi: 10.1152/physrev.00007.2007. Epub
[PubMed PMID: 18391177]
[14]
Imran M, Mahmood S. An overview of human prion diseases. Virology journal. 2011 Dec 24:8():559. doi: 10.1186/1743-422X-8-559. Epub 2011 Dec 24
[PubMed PMID: 22196171]
Level 3 (low-level) evidence
[15]
Zabel MD, Avery AC. Prions--not your immunologist's pathogen. PLoS pathogens. 2015 Feb:11(2):e1004624. doi: 10.1371/journal.ppat.1004624. Epub 2015 Feb 19
[PubMed PMID: 25695738]
[16]
Mead S, Whitfield J, Poulter M, Shah P, Uphill J, Campbell T, Al-Dujaily H, Hummerich H, Beck J, Mein CA, Verzilli C, Whittaker J, Alpers MP, Collinge J. A novel protective prion protein variant that colocalizes with kuru exposure. The New England journal of medicine. 2009 Nov 19:361(21):2056-65. doi: 10.1056/NEJMoa0809716. Epub
[PubMed PMID: 19923577]
[17]
Lee HS, Brown P, Cervenáková L, Garruto RM, Alpers MP, Gajdusek DC, Goldfarb LG. Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/methionine genotype. The Journal of infectious diseases. 2001 Jan 15:183(2):192-196
[PubMed PMID: 11120925]
[18]
Liberski PP. Kuru: a journey back in time from papua new Guinea to the neanderthals' extinction. Pathogens (Basel, Switzerland). 2013 Jul 18:2(3):472-505. doi: 10.3390/pathogens2030472. Epub 2013 Jul 18
[PubMed PMID: 25437203]
[19]
Sikorska B, Liberski PP, Sobów T, Budka H, Ironside JW. Ultrastructural study of florid plaques in variant Creutzfeldt-Jakob disease: a comparison with amyloid plaques in kuru, sporadic Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker disease. Neuropathology and applied neurobiology. 2009 Feb:35(1):46-59. doi: 10.1111/j.1365-2990.2008.00959.x. Epub 2008 May 30
[PubMed PMID: 18513219]
[20]
Kakulas BA, Lecours AR, Gajdusek DC. Further observations on the pathology of Kuru. (A study of the two cerebra in serial section). Journal of neuropathology and experimental neurology. 1967 Jan:26(1):85-97
[PubMed PMID: 6022166]
[21]
Hainfellner JA, Liberski PP, Guiroy DC, Cervénaková L, Brown P, Gajdusek DC, Budka H. Pathology and immunocytochemistry of a kuru brain. Brain pathology (Zurich, Switzerland). 1997 Jan:7(1):547-53
[PubMed PMID: 9034563]
[22]
Mathews JD. Review. The changing face of kuru: a personal perspective. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 2008 Nov 27:363(1510):3679-84. doi: 10.1098/rstb.2008.0085. Epub
[PubMed PMID: 18672465]
Level 3 (low-level) evidence
[24]
Cobb WA, Hornabrook RW, Sanders S. The EEG of kuru. Electroencephalography and clinical neurophysiology. 1973 Apr:34(4):419-27
[PubMed PMID: 4120316]
[25]
Stewart LA, Rydzewska LH, Keogh GF, Knight RS. Systematic review of therapeutic interventions in human prion disease. Neurology. 2008 Apr 8:70(15):1272-81. doi: 10.1212/01.wnl.0000308955.25760.c2. Epub
[PubMed PMID: 18391159]
Level 1 (high-level) evidence